

Bench to clinic: Innovations in immunodermatology and emerging treatment approaches

Friday, March 25, 2022, 7:00 PM – 9:00 PM

Omni Boston Hotel at the Seaport; Momentum A, B, C

(Dinner will be provided)

Speakers:



**Andrew Alexis,
MD, MPH**



**April Armstrong,
MD, MPH**



**Joslyn Kirby,
MD, MEd, MS**



**James G. Krueger,
MD, PhD**



**Eric Simpson,
MD, MCR**



**Bruce E. Strober,
MD, PhD, FAAD**

This program is independent and is not part of the official AAD Annual Meeting, as planned by its Scientific Assembly Committee.

This program does not qualify for Continuing Medical Education (CME) Credit.

For all attendees, please be advised that information such as your name and the value and purpose of any educational item, meal, or other items of value you receive may be publicly disclosed.

If you are licensed in any state or other jurisdiction, or are an employee or contractor of any organization or government entity, that limits or prohibits meals from pharmaceutical companies, please identify yourself so that you (and we) are able to comply with such requirements. This educational activity is not accredited. The program is developed by Janssen Biotech, Inc.

Speakers present on behalf of the company.

With the support of Janssen Pharmaceutical Companies of Johnson & Johnson.

Janssen Biotech Inc. 800 Ridgeview Drive Horsham, PA 19044

Date of preparation: February 2022

Program Description:

This session aims to discuss the unmet needs and recent innovations in immunodermatology, as well as emerging pathways and treatment approaches in psoriasis, atopic dermatitis and hidradenitis suppurativa.

The faculty will also discuss the need for diversity, equality and inclusion in dermatology.

Learning Objectives: Following this session, the attendee should be able to:

- Recognize the necessity for practicing clinical dermatologists to better understand the current unmet needs in their day-to-day management of patients with inflammatory skin diseases, namely psoriasis, atopic dermatitis, and hidradenitis suppurativa
- Describe the role of current and emerging cytokine-targeting pathways in psoriasis, atopic dermatitis, and hidradenitis suppurativa
- Understand how new data from available treatments or compounds in development can help address their patients' unmet needs in clinical practice

Program (All times are ET):

6:30 PM – 7:00 PM **Registration**

7:00 PM – 7:30 PM **Dinner**

7:30 PM – 7:35 PM **Welcome and introductions**

James G. Krueger, MD, PhD

7:35 PM – 7:55 PM **Immunology unraveled for common skin diseases: psoriasis, atopic dermatitis and hidradenitis suppurativa**

James G. Krueger, MD, PhD

7:55 PM – 8:05 PM **Atopic Dermatitis transformed: Pearls of diagnosis and management**

Eric Simpson, MD, MDR

8:05 PM – 8:15 PM **Pearls & pitfalls in hidradenitis suppurativa management**

Joslyn Kirby, MD, MEd

8:15 PM – 8:25 PM **Psoriasis - What is next?**

April Armstrong, MD, MPH

8:25 PM – 8:35 PM **Inflammatory dermatoses and diverse populations: Important considerations for skin of color**

Andrew Alexis, MD, MPH

8:35 PM – 8:55 PM **Fireside chat: Your burning questions**

All moderated by Bruce E. Strober, MD, PhD, FAAD

8:55 PM – 9:00 PM **Summary and close**

Bruce E. Strober, MD, PhD, FAAD